Table 1 Pre-treatment characteristics of patients enrolled (n = 85)
FLEEOX , n = 48 | XELOX, n = 37 | P value | |
|---|---|---|---|
Patients, n | 48 | 37 | |
Age, years) | 38 to 73 | 38 to 75 | |
Gender, n (%) | |||
Male | 35 (72.9) | 27 (73.0) | 1.00 |
Female | 13 (27.1) | 10 (27.0) | |
ECOG1 | |||
0 | 29 (60.4) | 21 (56.8) | 0.94 |
1 | 13 (27.1) | 11 (29.7) | |
2 | 6 (12.5) | 5 (13.5) | |
Site of lesion | |||
Cardia | 19 (39.6) | 17 (45.9) | 0.82 |
Gastric body | 15 (31.3) | 11 (29.7) | |
Gastric antrum | 14 (21.1) | 9 (24.4) | |
Degree of differentiation | |||
Severe | 3 (6.3) | 2 (5.4) | 0.57 |
Moderate | 13 (27.1) | 14 (37.8) | |
Mild | 32 (66.6) | 21 (56.8) | |
Pre-treatment stage, n (%) | |||
III | 20 (41.7) | 21 (56.8) | 0.191 |
IV | 28 (58.3) | 16 (43.2) | |
Reasons for non-resection | |||
Tumor and metastatic lymph nodes with encompassment of major blood vessels | 44 (91.7) | 35 (94.6) | 0.74 |
Liver metastasis | 1 (2.1) | 1 (2.7) | |
NO.16 group of lymph nodes | 3 (6.3) | 1 (2.7) |